目标价:$22.00
先说重点 :公司候选药物ATYR1923 的 ph2 肺结节病 (PS) 试验的最新数据为该药物和 aTyr 专注于 tRNA 合成酶信号传导的独家研究平台提供了概念验证。我认为 ATYR1923 是一个被低估的资产,有可能在 PS 治疗中获得惊人的地位,并且也有扩展到其他间质...查看全文
梦想照不进现实2021-09-14 18:58
$aTyr制药(LIFE)$ $Inovio制药(INO)$ $Vaxart(VXRT)$ 老美这些制药公司炒起来都一个套路,稍微有点好消息股价就一步到位,一旦不及预期,马上跌成🐶屎。查看全文
Meyes2021-09-14 08:47
aTyr制药昨夜星辰华尔街最闪亮的星星,飙升67%。
aTyr昨天宣布,其主要治疗候选药物ATYR1923的1b/2a期双盲安慰剂对照临床试验在37名肺结核病患者中取得了积极成果,这是一种主要形式的间质性肺病(ILD)。ATYR1923在所有剂量上都是安全的,耐受性良好,没有与药物相关的严重不良事件或免疫原性...查看全文
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-067989 Size: 5 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-067666 Size: 4 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-067668 Size: 4 KB 网页链接
$aTyr Pharma(LIFE)$ 8-K Current report, items 5.02, 5.05, 5.07, 8.01, and 9.01 Accession Number: 0000950170-24-065899 Act: 34 Size: 465 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064229 Size: 5 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064235 Size: 5 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064218 Size: 5 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064225 Size: 5 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064199 Size: 5 KB 网页链接
$aTyr Pharma(LIFE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-064209 Size: 5 KB 网页链接